Grifols (NASDAQ:GRFS) Shares Gap Down – What’s Next?

Shares of Grifols, S.A. (NASDAQ:GRFS) gapped down before the market opened on Thursday . The stock had previously closed at $7.40, but opened at $7.00. Grifols shares last traded at $7.15, with a volume of 362,744 shares traded.

Analysts Set New Price Targets

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Stock Performance

The stock’s 50 day moving average price is $7.75 and its 200 day moving average price is $8.21. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79.

Institutional Investors Weigh In On Grifols

A number of institutional investors have recently modified their holdings of the company. GAMMA Investing LLC lifted its position in shares of Grifols by 49.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 1,135 shares during the period. NBC Securities Inc. lifted its position in shares of Grifols by 2.8% during the 3rd quarter. NBC Securities Inc. now owns 52,181 shares of the biotechnology company’s stock valued at $463,000 after acquiring an additional 1,433 shares during the period. HighTower Advisors LLC lifted its position in shares of Grifols by 12.5% during the 3rd quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 1,546 shares during the period. Signaturefd LLC lifted its position in shares of Grifols by 66.2% during the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 2,153 shares during the period. Finally, US Bancorp DE raised its holdings in Grifols by 12.3% during the third quarter. US Bancorp DE now owns 20,663 shares of the biotechnology company’s stock worth $183,000 after buying an additional 2,256 shares during the last quarter.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.